首页> 外文期刊>Journal of Crohn’s & colitis >Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations
【24h】

Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations

机译:多次粪便菌群移植治疗的溃疡性结肠炎患者艰难梭菌感染的微生物组成分析

获取原文
获取原文并翻译 | 示例
           

摘要

Fecal microbiota transplantation (FMT) is a promising therapy for Clostridium difficile infection (CDI). However, questions remain regarding efficacy and safety in inflammatory bowel disease (IBD) patients, as well as longitudinal stability of donor stool composition. This report describes an IBD patient with two CDIs 18. months apart, each successfully treated with FMT with no IBD flares or complications. Microbiome composition analysis of patient samples during each infection revealed low-diversity microbiota patterns similar to those previously described in non-IBD patients with CDI and active IBD alone. Samples taken after each transplant demonstrated quick remodeling towards the donor's sample composition coinciding with symptom resolution. Of note, samples taken from the same donor 18. months apart reflected marked differences in microbiota abundances, suggesting that the use of single donors in FMT programs offers little benefit in ensuring predictability of donor stool composition over time. This report describes similar microbial composition patterns during CDI in IBD patients to those described previously in non-IBD patients, and supports FMT as safe and effective treatment for recurring CDI in this patient population.
机译:粪便菌群移植(FMT)是一种用于艰难梭菌感染(CDI)的有前途的疗法。然而,关于炎性肠病(IBD)患者的功效和安全性以及供体粪便成分的纵向稳定性仍然存在疑问。该报告描述了一个IBD患者,两个CDI间隔18个月,每个均成功接受FMT治疗,没有IBD发作或并发症。每次感染期间对患者样品进行的微生物组组成分析显示,低多样性微生物群模式类似于先前在仅具有CDI和活动性IBD的非IBD患者中描述的模式。每次移植后采集的样品均表现出对供体样品组成的快速重塑,与症状缓解相吻合。值得注意的是,从同一供者那里分离的样品在间隔18个月时反映出微生物群落丰度的显着差异,这表明在FMT计划中使用单个供体对确保供体粪便成分随时间的可预测性几乎没有好处。该报告描述了IBD患者在CDI期间的微生物组成模式与之前在非IBD患者中描述的相似,并支持FMT作为该患者人群中复发CDI的安全有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号